Transgene Biotek (526139)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me begin with a confession: This is exactly the kind of stock I would normally toss into the 'too hard' pile. Transgene Biotek has a market cap of ₹77 crore at ₹9.56 per share, but what does the business actually earn? The latest quarter shows sales of ₹0 crore and a net profit of ₹-0 crore. Full-year momentum is worse: sales fell 37.5%, and profit growth was minus 311%. A Piotroski F-score of 2 out of 9 is a red flag—it tells me the financial health is deteriorating, not improving. ROCE is -1.75%, so the company isn't earning a decent return on capital. The headline ROE of 28.30% might tempt a naive investor, but with zero revenue and losses, I consider it an accounting mirage. There is no dividend, so I get no cash while I wait. The price has run from ₹1.83 to ₹9.56, but a rising share price without rising earnings is just sentiment. Graham would ask: Where is the margin of safety? Book value, promoter holding, and debt/equity are unavailable, so I cannot calculate asset backing. This isn't value investing; it's speculation. For a healthcare service provider, India's long-term demand is real, but this particular company must first prove it can generate sales. I can only revisit if sustainable revenue reappears, profits turn positive, and the balance sheet is disclosed. Until then, I remain on the sidelines. Capital preservation comes before potential—and here, there is too little to preserve.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer